SCHEMBL7230489

SCHEMBL7230489

CC(=O)N1CCC(c2ccc(C(=O)O)cc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
QDPR P09417 2/20 0.60
KCNH2 Q12809 2/20 0.51
ADRB3 P13945 1/20 0.51
ADRA2C P18825 1/20 0.51
DRD1 P21728 1/20 0.51
DRD5 P21918 1/20 0.51
HTR1D P28221 1/20 0.51
HTR1E P28566 1/20 0.51
TSPO P30536 1/20 0.51
ADRA1A P35348 1/20 0.51
DRD3 P35462 1/20 0.51
HTR5A P47898 1/20 0.51
P2RY14 Q15391 1/20 0.51
PRKAB2 O43741 2/20 0.49
PRKAG1 P54619 2/20 0.49
PRKAA2 P54646 2/20 0.49
PRKAA1 Q13131 2/20 0.49
PRKAG3 Q9UGI9 2/20 0.49
PRKAG2 Q9UGJ0 2/20 0.49
PRKAB1 Q9Y478 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7287663 0.88 QDPR (0.62) QDPRKCNH2ADRB3ADRA2CDRD1
SCHEMBL4969354 0.86 CA12 (0.48) QDPRKCNH2HSD11B1CA12CA1
SCHEMBL1473424 0.84 QDPR (0.61) QDPRKCNH2NPY5RHSD11B1CA12
SCHEMBL7222401 0.83 CA12 (0.49) QDPRKCNH2HSD11B1CA12CA1
SCHEMBL12306056 0.83 CA12 (0.46) QDPRKCNH2HSD11B1CA12CA1
SCHEMBL1305458 0.83 HDAC3 (0.55) QDPRP2RY14PRKAB2PRKAG1PRKAA2
SCHEMBL7277302 0.83 QDPR (0.69) QDPRKCNH2PRKAB2PRKAG1PRKAA2
SCHEMBL12874043 0.83 QDPR (0.64) QDPRDRD3MCHR1NPY5RNPC1
SCHEMBL15379923 0.83 NAMPT (0.56) KCNH2HRH3
SCHEMBL22531787 0.83 HSD11B1 (0.49) QDPRKCNH2PRKAB2PRKAG1PRKAA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3184520-B1 SALT OF MONOCYCLIC PYRIDINE DERIVATIVE AND CRYSTAL THEREOF EISAI R&D MAN CO LTD (JP) 2022-03-23 EP disclosed
US-20220041559-A1 BENZO-AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS ROTTAPHARM BIOTECH S.R.L. (IT) 2022-02-10 US disclosed
US-9951047-B2 Salt of monocyclic pyridine derivative and crystal thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2018-04-24 US disclosed
US-9951047-B2 Salt of monocyclic pyridine derivative and crystal thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2018-04-24 US disclosed
US-9951047-B2 Salt of monocyclic pyridine derivative and crystal thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2018-04-24 US disclosed
US-20170217935-A1 SALT OF MONOCYCLIC PYRIDINE DERIVATIVE AND CRYSTAL THEREOF EISAI R&D MANAGEMENT CO., LTD. (JP) 2017-08-03 US disclosed
US-20170217935-A1 SALT OF MONOCYCLIC PYRIDINE DERIVATIVE AND CRYSTAL THEREOF EISAI R&D MANAGEMENT CO., LTD. (JP) 2017-08-03 US disclosed
US-20170217935-A1 SALT OF MONOCYCLIC PYRIDINE DERIVATIVE AND CRYSTAL THEREOF EISAI R&D MANAGEMENT CO., LTD. (JP) 2017-08-03 US disclosed
EP-3184520-A1 SALT OF MONOCYCLIC PYRIDINE DERIVATIVE AND CRYSTAL THEREOF Eisai R&D Management Co., Ltd. (JP) 2017-06-28 EP disclosed
EP-3184520-A1 SALT OF MONOCYCLIC PYRIDINE DERIVATIVE AND CRYSTAL THEREOF Eisai R&D Management Co., Ltd. (JP) 2017-06-28 EP disclosed
US-20140235614-A1 MONOCYCLIC PYRIDINE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-08-21 US disclosed
US-20140235614-A1 MONOCYCLIC PYRIDINE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-08-21 US disclosed
US-20030153604-A1 Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds AVENTIS PHARMACEUTICALS INC. 2003-08-14 US disclosed
US-6541505-B1 Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. AVENTIS PHARMACEUTICALS INC. 2003-04-01 US disclosed
CN-1333766-A Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds as factor xainhibitors AVENTIS PHARM PROD INC (US) 2002-01-30 CN disclosed
EP-1140901-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS Aventis Pharmaceuticals Products Inc. (US) 2001-10-10 EP disclosed
WO-2000039087-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-07-06 WO disclosed
EP-0528369-B1 Cyclic imino derivatives, pharmaceutical compositions containing them and process for their preparation BOEHRINGER INGELHEIM PHARMA (DE) 1999-11-24 EP disclosed
US-5455348-A Anticoagulants Thomae, Karl (DE) 1995-10-03 US disclosed
EP-0528369-A2 Cyclic imino derivatives, pharmaceutical compositions containing them and process for their preparation Dr. Karl Thomae GmbH (DE) 1993-02-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170217935-A1 SALT OF MONOCYCLIC PYRIDINE DERIVATIVE AND CRYSTAL THEREOF MPST, SLC25A1, SLC16A1 QDPR 1081/4885KCNH2 2761/4885ADRB3 4597/4885
US-20220041559-A1 BENZO-AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS PDXK, MAP4K2, PLK2 QDPR 3733/4885KCNH2 3042/4885ADRB3 2465/4885
US-20140235614-A1 MONOCYCLIC PYRIDINE DERIVATIVE FGFR2, FGFR1, FGFR3 QDPR 182/4885KCNH2 1041/4885ADRB3 525/4885
US-20030153604-A1 Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds SERPINC1, F2, F11 QDPR 2464/4885KCNH2 3608/4885ADRB3 2603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.